Brand Name
Cosopt
Generic Name
Dorzolamide
View Brand Information FDA approval date: June 01, 2009
Classification: beta-Adrenergic Blocker
Form: Solution
What is Cosopt (Dorzolamide)?
Dorzolamide hydrochloride ophthalmic solution, USP is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride ophthalmic solution, USP is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Efficacy and Tolerability of Simbrinza and Rocklatan vs. Cosopt
Summary: A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.